Track Aethlon Medical, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Aethlon Medical, Inc. AEMD · Stock Open Aethlon Medical, Inc. in new tab

5.30 USD
P/E
0.01
EPS
-33.33
P/B
0.50
ROE
-160.91
Beta
1.23
Target Price
13.25 USD
Aethlon Medical, Inc. logo

Aethlon Medical, Inc.

🧾 Earnings Recap – Q3 2026

Aethlon Medical demonstrated steady progress in its Hemopurifier platform amidst ongoing clinical trials and strategic operational efficiencies in Q3 FY2026.

  • Continued enrollment and treatment efforts in the Australian oncology trial indicate positive patient interest and safety outcomes, with no serious adverse events reported so far.
  • Ongoing operating expense reductions year-to-date reflect disciplined cost management and financial prudence.
  • Advancements in EV research support the Hemopurifier's potential as a multi-indication therapeutic platform, broadening its future applications.
  • Collaboration with Stavro on simplifying the Hemopurifier treatment procedure aims to enhance clinical flexibility and accessibility.
  • Exploration of the Hemopurifier's role in addressing other health conditions, including Long COVID and various autoimmune diseases, suggests opportunities for pipeline expansion.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 15, 2027
P/E0.01
EPS-33.33
Book Value10.89
Price to Book0.50
Debt/Equity7.07
% Insiders3.126%
Estimates
Forward P/E-9.63
Forward EPS-0.57
Target Mean Price13.25

DCF valuation

Model fair value for Aethlon Medical, Inc. (AEMD)
Result
Sign in to run the valuation for AEMD.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
2 analysts · consensus None · mean target 13.25 USD (low 1.50, high 25.00) · as of 10 Nov 2026
Low 1.50
Mean 13.25
High 25.00
Price 5.30
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Aethlon Medical, Inc. Logo Aethlon Medical, Inc. Analysis (AEMD)

United States Health Care Official Website Stock

Is Aethlon Medical, Inc. a good investment? Aethlon Medical, Inc. (AEMD) is currently trading at 5.30 USD. Market analysts have a consensus price target of 13.25 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 0.01. This relatively low multiple may signal that Aethlon Medical, Inc. is undervalued compared to historical market norms.

Earnings Schedule: Aethlon Medical, Inc. is expected to release its next earnings report on Feb. 15, 2027. The market consensus estimate for Forward EPS is -0.57.

Investor FAQ

Does Aethlon Medical, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Aethlon Medical, Inc.?

Aethlon Medical, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 15, 2027. The company currently has a trailing EPS of -33.33.

Company Profile

Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company was founded in 1984 and is based in San Diego, California.

Exchange Ticker
FRA (Germany) EJU.F
NCM (Australia) AEMD
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
April 14, 2015 1:50
Oct. 15, 2019 0.07
Oct. 5, 2023 1:10
June 9, 2025 0.12
Oct. 20, 2025 1:10
Aug. 4, 2026 1:5
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion